Market closed
Sonnet Biotherapeutics Holdings/$SONN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sonnet Biotherapeutics Holdings
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Ticker
$SONN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
13
ISIN
US83548R4020
Website
SONN Metrics
BasicAdvanced
$4.1M
-
-$9.05
1.01
-
Price and volume
Market cap
$4.1M
Beta
1.01
52-week high
$1.70
52-week low
$1.10
Average daily volume
41K
Financial strength
Current ratio
2.154
Quick ratio
1.771
Long term debt to equity
0.585
Total debt to equity
2.749
Management effectiveness
Return on assets (TTM)
-133.99%
Return on equity (TTM)
-285.35%
Valuation
Price to revenue (TTM)
1.386
Price to book
0.99
Price to tangible book (TTM)
0.99
Price to free cash flow (TTM)
-0.164
Growth
Revenue change (TTM)
674.14%
Earnings per share change (TTM)
-85.07%
3-year revenue growth (CAGR)
17.69%
3-year earnings per share growth (CAGR)
-82.76%
SONN News
AllArticlesVideos
Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit
GlobeNewsWire·2 weeks ago
Sonnet Releases Virtual Investor "What This Means" Segment
GlobeNewsWire·4 weeks ago
Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Sonnet Biotherapeutics Holdings stock?
Sonnet Biotherapeutics Holdings (SONN) has a market cap of $4.1M as of May 14, 2025.
What is the P/E ratio for Sonnet Biotherapeutics Holdings stock?
The price to earnings (P/E) ratio for Sonnet Biotherapeutics Holdings (SONN) stock is 0 as of May 14, 2025.
Does Sonnet Biotherapeutics Holdings stock pay dividends?
No, Sonnet Biotherapeutics Holdings (SONN) stock does not pay dividends to its shareholders as of May 14, 2025.
When is the next Sonnet Biotherapeutics Holdings dividend payment date?
Sonnet Biotherapeutics Holdings (SONN) stock does not pay dividends to its shareholders.
What is the beta indicator for Sonnet Biotherapeutics Holdings?
Sonnet Biotherapeutics Holdings (SONN) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.